Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of IM-250 in Healthy Volunteers
NCT06435507Phase 1Completed
- Sponsor
- Innovative Molecules GmbH
- Start
- Apr 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adibelivir in herpes simplex virus infection (4 cohorts), sponsored by Innovative Molecules GmbH. Primary endpoint: Dose-limiting toxicities at 28 days. Started Apr 2023; status: completed.
02
Drugs
adibelivir
03
Conditions
herpes simplex virus infection
Beyond the preview
Go deeper on NCT06435507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06435507.